Impact of prior PARP inhibitor exposure on the efficacy of platinum-based chemotherapy in platinum-sensitive recurrent ovarian cancer: a propensity score-matched analysis
{{output}}
Background: To evaluate the efficacy of platinum-based chemotherapy in platinum-sensitive recurrent ovarian cancer (PSROC) between patients with and without prior exposure to poly(ADP-ribose) polymerase inhibitor (PARPi). ... ...
